L-648,051

L-648,051 is a small molecule drug that acts as a selective antagonist of the leukotriene D4 (LTD4) receptor, also known as a cysteinyl-leukotriene receptor antagonist. It was developed by Merck & Co (Merck Sharp & Dohme Corp.) and investigated primarily for the treatment of asthma and cardiac arrhythmias. The drug was administered via inhalation in clinical studies and demonstrated dose-dependent inhibition of LTD4-induced bronchoconstriction in humans without affecting histamine-induced bronchospasm. It showed potential utility in assessing the role of leukotrienes in asthma and other lung diseases but did not progress beyond phase II clinical trials before development was discontinued[1][2][3].

Other names

4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid